" /> Amivantamab - CISMeF





Preferred Label : Amivantamab;

NCIt synonyms : Anti-EGFR/c-Met Bispecific Antibody JNJ-61186372; Amivantamab-vmjw;

NCIt definition : A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), with potential antineoplastic activity. Upon administration, amivantamab simultaneously targets and binds to wild-type or certain mutant forms of both EGFR and cMet expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and cMet-mediated signaling pathways. In addition, binding results in receptor degradation, which further inhibits EGFR- and cMet-mediated signaling. JNJ-61186372 also causes antibody-dependent cellular cytotoxicity (ADCC). Altogether, this results in the inhibition of tumor cell proliferation. EGFR and cMet, both upregulated or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.;

UNII : 0JSR7Z0NB6;

CAS number : 2171511-58-1;

Drug name : Rybrevant;

Molecule name : JNJ-61186372; JNJ-611; CNTO-4424; JNJ 61186372;

NCI Metathesaurus CUI : CL503840;

Codes from synonyms : 29753;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
30/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.